New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
09:57 EDTSRPTSarepta CSO had 'serious disagreements' with CEO, WSJ reports
Sarepta's recently terminated Chief Scientific Officer Arthur Krieg said he had "serious disagreements" with CEO Chris Garabedian, Wall Street Journal reported last night, citing comments from a phone interview. Krieg's termination follows other management departures and "interrupts" the process" of preparing eteplirsen paperwork for the FDA, the Journal added, citing a person familiar with the matter. Recall that The Street's Adam Feuerstein reported yesterday that Krieg had no role in the clinical development of eteplirsen. Reference Link
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
15:14 EDTSRPTTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 18, 2014
09:17 EDTSRPTSarepta announces first patient dosed in Eteplirsen study
Subscribe for More Information
November 17, 2014
08:44 EDTSRPTNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
November 12, 2014
17:20 EDTSRPTSarepta doses first patient in study of muscular dystrophy candidate Eteplirsen
Subscribe for More Information
November 6, 2014
07:07 EDTSRPTSarepta decreases FY14 loss from operations view to $110M-$120M
The company decreased its FY14 loss from operations view to $110M-$120M from $135M-$145M. The company expects that its current financial position and prudent expense management will support the execution of its strategic business plan.
07:05 EDTSRPTSarepta reports Q3 EPS (70c), consensus (96c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use